Does Rallies show 13F holders for BCTX?

Yes. Rallies tracks hedge fund and 13F ownership data for BCTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BCTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BCTX. It does not provide personalized investment advice.

BCTX (Briacell Therapeutics Corp. Common Shares) Stock Analysis - Hedge Fund Holdings

Briacell Therapeutics Corp. Common Shares (BCTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCTX trades at $3.98 with a market cap of $24.29M and a P/E ratio of -0.06. BCTX moved +9.69% today. Year to date, BCTX is -49.28%; over the trailing twelve months it is -89.10%. Its 52-week range spans $2.98 to $214.50. Rallies surfaces BCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BCTX stock?

Hedge funds tracked by Rallies that own BCTX include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Briacell Therapeutics Corp. Common Shares.

BCTX Key Metrics

Key financial metrics for BCTX
Metric	Value
Price	$3.98
Market Cap	$24.29M
P/E Ratio	-0.06
EPS	$-62.19
Dividend Yield	0.00%
52-Week High	$214.50
52-Week Low	$2.98
Volume	1.20K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-26.56M
Gross Margin	0.00%

Top Hedge Funds Holding BCTX

Renaissance Technologies holds 15.00K shares of BCTX, changed +22.95% as of Jun 30, 2024.
Citadel Advisors holds 5.80K shares of BCTX, changed -91.63% as of Dec 31, 2024.

Latest BCTX News

BriaCell Adds Next-Gen Ovarian Cancer Immunotherapy Bria-OVA+ After Phase 2 Breast Success — May 15, 2026
BriaCell Completes Bria-PROS+ Manufacturing, Eyes Phase 1/2a Prostate Cancer Trial — May 14, 2026
BriaCell Adds Penn Medicine’s Abramson Cancer Center to Phase 3 Breast Cancer Trial — May 13, 2026
BriaCell Unveils Six ASCO 2026 Presentations with Phase 2 Survival Data — Apr 27, 2026
BriaCell to Showcase Positive Phase 3 QOL Data and Bria-OTS+ Preclinical Findings — Mar 18, 2026

Recent BCTX Insider Trades

Lustig Marc bought 902.93K (~$2.00M) on May 14, 2024.
Bondarenko Jamieson bought 28.00K (~$128.24K) on Dec 28, 2022.
Bondarenko Jamieson bought 22.00K (~$117.70K) on Dec 20, 2022.

BCTX Analyst Consensus

BCTX analyst coverage data. Average price target: $0.00.

Common questions about BCTX

Who owns BCTX stock?: Hedge funds tracked by Rallies that own BCTX include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Briacell Therapeutics Corp. Common Shares.
Does Rallies show 13F holders for BCTX?: Yes. Rallies tracks hedge fund and 13F ownership data for BCTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BCTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BCTX. It does not provide personalized investment advice.